Preventing cluster headache attacks with verapamil

The standard first-line preventive (at a sufficiently high dose)

Verapamil is a heart medication used as the first-line preventive treatment for cluster headache. Its effect on cluster headache was first described in 1983, in a series of five patients.^[6][7] If your neurologist or headache specialist is familiar with cluster headache, verapamil will almost certainly be the first treatment they offer, regardless of whether your cluster headaches are episodic or chronic.

The 2023 European Academy of Neurology guideline gives it a consensus recommendation endorsing verapamil as the primary preventive therapy for cluster headache, and in 2025 the World Health Organization added verapamil to its Model List of Essential Medicines specifically for cluster headache.^[2][3] Despite its routine use as the main preventive treatment, verapamil is used off-label for cluster headache: no regulator has approved it specifically for this use.^[8]

The doses used for cluster headache (240 to 960 mg/day, sometimes higher) are roughly double the doses used for high blood pressure, and they require electrocardiogram (ECG) monitoring to use safely.^[2] During titration, about 1 in 3 patients develop a slow heart rate and about 1 in 5 develop a change in heart rhythm or conduction.^[4][2] Most of these changes are mild and managed by adjusting the dose, but they're the reason monitoring is a must.

---

How to take verapamil for cluster headache

Verapamil is taken daily, at a dose that increases slowly over weeks. It is used to prevent future attacks rather than to abort an attack in progress.

A typical protocol might look as follows, starting at the beginning of your cluster cycle (or, ideally, shortly before; or anytime for chronic patients):

1. Your doctor will do a baseline ECG. If everything looks good, you will then start taking 240 mg/day of immediate-release verapamil (80 mg three times daily).
2. If you're in a cycle, a short course of prednisone (or an occipital nerve block) may be prescribed alongside verapamil. These treatments may reduce attacks during the 2 to 3 weeks while verapamil starts to take effect (but they cannot be used long-term).
3. You then increase by 80 mg every 1 to 2 weeks, with an ECG before each increase. If you are already in your cycle, a faster increase might be possible.
4. Most patients settle in the 360 to 720 mg/day range, though some respond at lower doses. However, some patients need 960 to 1,200 mg/day.
5. Once you reach a working dose, you stay there. Episodic patients stay on verapamil through the whole cycle plus a few weeks, then taper down gradually. Chronic patients stay on it indefinitely.
6. ECGs continue regularly for as long as you're on verapamil, because changes can appear even after years on a stable dose.^[2][9] Guidelines don't set a fixed interval; at high doses, we suggest asking your doctor for an ECG every 2 to 6 months.

See the protocol page for the full regimen.

A typical verapamil protocol.

---

Verapamil's effectiveness

The available data are encouraging, but the precise proportion of patients who achieve relief and the magnitude of that benefit remain unclear.

In a placebo-controlled randomized trial, 80% of episodic patients on 360 mg/day had more than a 50% reduction in attacks after 14 days, compared with 0% on placebo.^[1] A pooled analysis of the episodic patients in two open-label studies (85 patients) found that about 87% either stopped having attacks or had at least 50% fewer attacks.^[10]

Data from patient surveys is more mixed. A systematic review of surveys by Rusanen and colleagues found that only about 50% of patients who had tried verapamil responded positively.^[5] Surveys are prone to several biases, and it is also possible that some respondents didn't follow the correct protocol (in particular, not reaching a high enough dose, or not waiting long enough).

For the meaningful minority who don't respond at any dose, other options exist. We recommend our guide on preventive treatments to learn more about them and find something that works for you.

---

References (10)

1. ↩ Leone M, D'Amico D, Frediani F, et al. (2000). Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology, 54(6), 1382–1385. Link
2. ↩ May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, et al. (2023). European Academy of Neurology guidelines on the treatment of cluster headache. European Journal of Neurology, 30(10), 2955–2979. doi:10.1111/ene.15956
3. ↩ Tassorelli C, Lampl C, Leone M, et al. (2026). WHO's essential medicines list: additions for migraine and cluster headache. Cephalalgia. Link
4. ↩ Cohen AS, Matharu MS, Goadsby PJ (2007). Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology, 69(7), 668–675. Link
5. ↩ Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M (2022). Self-reported efficacy of treatments in cluster headache: a systematic review of survey studies. Current Pain and Headache Reports, 26(8), 623–637. Link
6. ↩ Meyer JS, Hardenberg J (1983). Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache, 23(6), 266–277. doi:10.1111/j.1526-4610.1983.hed2306266.x
7. ↩ Coppola G, Arruda MA, Ashina M, Barloese M, et al. (2025). Hallmarks of primary headache: part 3 – cluster headache. Journal of Headache and Pain, 26, 196. doi:10.1186/s10194-025-02145-6
8. ↩ de Freitas Dias B, Robinson CL, Villar-Martinez MD, Ashina S, Goadsby PJ (2025). Current and novel therapies for cluster headache: a narrative review. Pain and Therapy, 14(1), 1–19. doi:10.1007/s40122-024-00674-7
9. ↩ Lantéri-Minet M, Silhol F, Piano V, Donnet A (2011). Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day). Journal of Headache and Pain, 12(2), 173–178. doi:10.1007/s10194-010-0289-x
10. ↩ Pompilio G, Migliore A, Integlia D (2021). Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs. European Review for Medical and Pharmacological Sciences, 25(3), 1631–1640. doi:10.26355/eurrev_202102_24874